Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Open-Label Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Combination Single Tablet Regimen (STR) in Virologically-Suppressed, HIV-1 Positive Subjects

NCT01815736 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT01815736
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01815736 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Open-Label Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Combination Single Tablet Regimen (STR) in Virologically-Suppressed, HIV-1 Positive Subjects
Lead sponsor
Gilead Sciences
Phase
Phase 3
Overall status
Completed
Start date
March 27, 2013
Completion date
April 1, 2020
Enrollment
1,443 (actual)
Sites
167

Conditions

As the registry lists them; a condition with its own page is linked.

hiv, hiv infections